PKD Cures Act
Sponsored By: Representative Wasserman Schultz, Debbie [D-FL-25]
Introduced
Summary
Expand and accelerate NIH research on polycystic kidney disease. The bill would push the National Institutes of Health to grow basic, translational, and clinical PKD research and to develop a public roadmap that integrates tools like artificial intelligence and precision medicine.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
More research for polycystic kidney disease
If enacted, the NIH Director would expand research on polycystic kidney disease (PKD). The expansion would fund basic studies of genes and molecules. It would also support translational work on biomarkers and drug targets, and clinical trials testing treatments. The Director would set up a working group with PKD experts and patient-group representatives. That group would make a research roadmap and a plan to use AI and precision medicine. The group would have to send a report to Congress within 24 months after enactment. The bill does not specify funding amounts.
Sponsors & CoSponsors
Sponsor
Wasserman Schultz, Debbie [D-FL-25]
FL • D
Cosponsors
Rep. Miller, Carol D. [R-WV-1]
WV • R
Sponsored 6/4/2026
Rep. Cleaver, Emanuel [D-MO-5]
MO • D
Sponsored 6/4/2026
Rep. Bacon, Don [R-NE-2]
NE • R
Sponsored 6/4/2026
Rep. Wilson, Joe [R-SC-2]
SC • R
Sponsored 6/29/2026
Rep. Van Drew, Jefferson [R-NJ-2]
NJ • R
Sponsored 7/9/2026
Rep. Davids, Sharice [D-KS-3]
KS • D
Sponsored 7/13/2026
Rep. DelBene, Suzan K. [D-WA-1]
WA • D
Sponsored 7/15/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov